Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Melanomas are highly aggressive neoplasms resistant to most conventional therapies. These tumors result from the interaction of altered intracellular tumor suppressors and oncogenes with the microenvironment in which these changes occur. We previously demonstrated that physiologic skin hypoxia contributes to melanomagenesis in conjunction with Akt activation. Here we show that Notch1 signaling is elevated in human melanoma samples and cell lines and is required for Akt and hypoxia to transform melanocytes in vitro. Notch1 facilitated melanoma development in a xenograft model by maintaining cell proliferation and by protecting cells from stress-induced cell death. Hyperactivated PI3K/Akt signaling led to upregulation of Notch1 through NF-kappaB activity, while the low oxygen content normally found in skin increased mRNA and protein levels of Notch1 via stabilization of HIF-1alpha. Taken together, these findings demonstrate that Notch1 is a key effector of both Akt and hypoxia in melanoma development and identify the Notch signaling pathway as a potential therapeutic target in melanoma treatment.

Original publication

DOI

10.1172/JCI36157

Type

Journal article

Journal

J Clin Invest

Publication Date

11/2008

Volume

118

Pages

3660 - 3670

Keywords

Animals, Cell Line, Tumor, Genes, Reporter, Humans, Hypoxia, Hypoxia-Inducible Factor 1, alpha Subunit, Luciferases, Male, Melanocytes, Melanoma, Mice, Mice, SCID, NF-kappa B, Proto-Oncogene Proteins c-akt, RNA, Messenger, Receptor, Notch1, Signal Transduction, Up-Regulation, Xenograft Model Antitumor Assays